Is TG Therapeutics (TGTX) Fully Valued Following Its New Schizophrenia Trial Launch?
Why TG Therapeutics Stock Is Back in Focus
TG Therapeutics (TGTX) has attracted fresh attention after launching a Phase 2 trial of BRIUMVI in adults with treatment-resistant schizophrenia. This extends its CD20-focused approach beyond multiple sclerosis and into severe psychiatric disease.
See our latest analysis for TG Therapeutics.
The BRIUMVI schizophrenia trial arrives after a strong run in TG Therapeutics' share price, with a 90 day share price return of 69.04% and year to date share price return of 95.08%. The 3 year total shareholder return of 158.46% points to solid long term gains.
If this kind of clinical momentum has your attention, it could be a good moment to size up other opportunities in healthcare focused AI by scanning 41 healthcare AI stocks
Given how sharply TG Therapeutics has re-rated on clinical news, are you looking at a business whose fundamentals now justify the price, or at a mood swing that has run ahead of the numbers and the valuation work to come?
Most Popular Narrative: 10.5% Overvalued
The most followed narrative values TG Therapeutics at $51.71 per share, compared with the last close at $57.12, putting that story on the cautious side of current pricing.
The analysts have a consensus price target of $51.71 for TG Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $83.0, and the most bearish reporting a price target of just $17.0.
Want to understand why this narrative lands below the current TG Therapeutics share price? The story leans on brisk revenue expansion, shifting profit margins, and a future earnings multiple that is tighter than many growth focused biotechs. The exact mix of assumptions makes the fair value sensitive to even small changes in those inputs.
Result: Fair Value of $51.71 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, TG Therapeutics still carries clear pressure points, with heavy reliance on BRIUMVI, as well as rising competition and pricing scrutiny in multiple sclerosis treatments that could reset expectations.
Find out about the key risks to this TG Therapeutics narrative.
Another View on TG Therapeutics Valuation
The analyst narrative suggests TG Therapeutics is around 10.5% overvalued against a $51.71 fair value, yet the current P/E of 17.5x sits below both peers at 22.8x and a fair ratio of 23.9x. That gap points to a very different story: is sentiment or the spreadsheet out of line?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment clearly mixed around TG Therapeutics, use that tension as a prompt to act now. Review both the risks and rewards, and decide where you stand using the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond TG Therapeutics?
If you are reassessing TG Therapeutics, do not stop there, broaden your watchlist now so you are not relying on a single story.
- Spot potential bargains early by scanning screener containing 19 high quality undiscovered gems before other investors start paying attention.
- Prioritize resilience and sleep easier at night by filtering for companies in the 78 resilient stocks with low risk scores that align with your comfort level.
- Target stronger fundamentals by reviewing stocks in the solid balance sheet and fundamentals stocks screener (47 results) that pair healthier finances with room for future decisions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com